Every 8-K that TherapeuticsMD, Inc. (TXMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TXMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TXMD filings page.
TherapeuticsMD, Inc. reported its financial results for the quarter ended June 30, 2026 and furnished them in a press release. The business now operates as a pharmaceutical royalty company, primarily collecting royalties from licensees, and has exited research, development, and commercial operations.
The company states that it is evaluating potential strategic alternatives, which may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions. It highlights multiple risk factors, including reliance on licensees to commercialize products, reimbursement and regulatory uncertainties, Nasdaq listing risk, management transitions, intellectual property and competitive pressures, and a disclosed risk regarding the company’s ability to continue as a going concern.
TherapeuticsMD, Inc. furnished an update on its business by issuing a press release with financial results for the three months ended March 31, 2026. The company now operates as a pharmaceutical royalty business, primarily collecting royalties from licensees instead of running its own research, development, or commercial operations.
The press release also discusses an ongoing evaluation of potential strategic alternatives, which may include transactions such as an acquisition, merger, sale of assets, or other business combinations. Extensive forward-looking statement language highlights uncertainties around royalty revenues, operating wind-down, Nasdaq listing status, and the company’s ability to continue as a going concern.
TherapeuticsMD, Inc. filed a report describing that it has released its financial results for the full year ended December 31, 2025, via a press release furnished as an exhibit. The company now operates as a pharmaceutical royalty business and no longer conducts research, development, or commercial operations.
The release references topics such as net loss, license revenues, operating expenses, balance sheet and an evaluation of potential strategic alternatives, and it includes extensive forward‑looking statement language highlighting risks around licensee performance, ongoing disputes, Nasdaq listing status, and the company’s ability to continue as a going concern.
TherapeuticsMD, Inc. has appointed Carr, Riggs & Ingram, L.L.C. (CRI) as its new independent registered public accounting firm, effective January 15, 2026. This change follows a transaction in which CRI acquired certain assets related to the capital markets practice of the prior auditor, Berkowitz Pollack Brant Advisors + CPAs (BPB), which has ceased serving as the company’s auditor.
BPB’s audit reports for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain adverse opinions or disclaimers, but they did include an explanatory paragraph about uncertainty regarding the company’s ability to continue as a going concern. The company reports there were no disagreements or reportable events with BPB, and it states that neither it nor its representatives consulted with CRI on accounting or auditing matters before CRI’s appointment.
TherapeuticsMD, Inc. reported the results of its 2025 annual meeting of stockholders held on December 15, 2025. On the October 20, 2025 record date there were 11,574,362 common shares outstanding, and 6,842,247 shares were represented, establishing a quorum.
Stockholders elected all four director nominees, each receiving about 5.1–5.2 million votes in favor. They approved, on a non-binding basis, the 2024 compensation of named executive officers with 5,162,545 votes for, 81,614 against and 8,293 abstentions. Investors also supported holding future advisory votes on executive pay every year, with 5,184,870 votes for the 1‑year frequency, and the board chose to follow this annual schedule.
Stockholders ratified Berkowitz Pollack Brant Advisors + CPAs, LLP as independent auditor for the year ending December 31, 2025, with 6,768,667 votes for. They also approved an amendment to increase authorized common stock to 640,000,000 shares, with 6,265,554 votes for, 548,884 against and 27,809 abstentions.
TherapeuticsMD, Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and the disclosure appears under Item 7.01, with Item 2.02 incorporating that information by reference.
The company notes the information is furnished, not filed, under the Exchange Act. The common stock trades on Nasdaq under the symbol TXMD.
TherapeuticsMD, Inc. disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02 via Item 7.01. The filing makes clear the material in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and includes an explicit disclaimer that the company has no obligation to publicly update any forward-looking statements. The report lists the press release and an Inline XBRL cover page as exhibits.